The FDA approves Inluriyo-Verzenio combo for ESR1-mutated breast cancer; EMBER-3 data double PFS, with supply chain and diagnostics implications for manufacturers.
News|Articles|August 30, 2017
PTSM: Pharmaceutical Technology Sourcing and Management
- PTSM: Pharmaceutical Technology Sourcing and Management-09-06-2017
- Volume 12
- Issue 9
Thermo Fisher Scientific Acquires Patheon
Author(s)Pharmaceutical Technology Editors
Thermo Fisher Scientific has completed the previously announced acquisition of Patheon for approximately $7.2 billion.
Advertisement
On Aug. 29, 2017, Thermo Fisher Scientific announced its completed acquisition of Patheon, a contract development and manufacturing organization (CDMO) serving the pharmaceutical and biotechnology sectors, for approximately $7.2 billion. The close follows the company’s
"We're pleased to complete our acquisition of Patheon and look forward to the significant value this transaction will create for our customers and our shareholders," said Marc Casper, CEO and president of Thermo Fisher Scientific, in a company press release. "By adding Patheon's highly complementary CDMO capabilities to our leading clinical trials services and bioproduction technologies, we will be an even stronger partner for our pharmaceutical and biotech customers. We're delighted to welcome our Patheon colleagues to the Thermo Fisher team and excited about the new opportunities we have to help our customers accelerate innovation and enhance productivity by leveraging our combined strengths."
Having generated fiscal 2016 revenue of approximately $1.9 billion, Patheon will become part of Thermo Fisher's laboratory products and services segment.
Source:
Articles in this issue
about 9 years ago
Evolution of Analytical Tools Advances Pharma, But Challenges Remainabout 9 years ago
Reducing Risks Inherent with Cell-Culture Mediaabout 9 years ago
Managing Risk for Biomanufacturing Raw Materialsabout 9 years ago
Lonza Expands Capabilities for Drug Product Servicesabout 9 years ago
Corden Pharma Facility in Italy is Cleared by FDAabout 9 years ago
Cambrex Invests in Analytical Laboratory Expansionabout 9 years ago
Swiss CDMO Expands GMP Manufacturing Capabilitiesabout 9 years ago
FDA Releases Supply Chain GuidanceAdvertisement
Related to this article
The Leadership Summit will bring senior pharma executives together to discuss supply chain resilience, medicine security, and manufacturing capacity amid growing geopolitical fragmentation.
This week, the FDA opened applications for its Expedited IND Pilot, quality experts presented at the PDA/FDA Joint Regulatory Conference, and Hovione expanded its spray drying capacity.
Christy Owings, Thermo Fisher, explains clinical trial supply chain risks in Latin America, importer-of-record strategy, AI, and eCOA delays.
PharmTech AI Pulse Check debuts: pharma experts tackle GxP 'slop,' multi-agent validation risk, OCR document mining, personalized mRNA cancer therapy.
Andrea K. Kerrigan, FDA, outlines how validation, data integrity, and QRM determine whether digital tools and AI strengthen or undermine CGMP compliance.
PharmTech spoke with Tara Dougal, event director for pharma at Informa Markets, about trends impacting the pharmaceutical industry and how CPHI Milan is addressing these areas this year.
Andrew Parker, PhD, executive drug development consultant, Quotient Sciences, explains how AI is integrated into pharmaceutical development.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Inluriyo-Verzenio Combo Doubles PFS, Adds Oral Complexity
2
Can AI Agents Satisfy CGMP Documentation Requirements?
3
PharmTech Weekly Roundup—September 18, 2026
4
CPHI Milan Brings Back Leadership Summit as Supply Chain and Manufacturing Pressures Ramp Up
5